Ligand Pharmaceuticals LGND Accrued Royalties
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrentAndNoncurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Questions, answered.
- What is Ligand Pharmaceuticals's accrued royalties?
- Ligand Pharmaceuticals (LGND) reported accrued royalties of $18.03M in Q1 2026.
- How has Ligand Pharmaceuticals's accrued royalties changed year-over-year?
- Ligand Pharmaceuticals's accrued royalties increased by 136.2% year-over-year, from $7.63M to $18.03M.
- What is the long-term trend for Ligand Pharmaceuticals's accrued royalties?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's accrued royalties has grown at a 1005.3% compound annual growth rate (CAGR), from $12K to $16.2M.